Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: selective estrogen receptor modulators - Bionovo

Drug Profile

Research programme: selective estrogen receptor modulators - Bionovo

Alternative Names: BN-AA-003-NY; BN-AM-008-XG; BN-AO-014; BN-CB-045; BN-DF-037; BN-ES-022; BN-EU-036; BN-GU-005-DHP; BN-OB-026; BN-PC-049-BK; BN-RP-006-OHA

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bionovo
  • Class
  • Mechanism of Action Estrogen receptor beta agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Female sexual dysfunction; Joint disorders; Menopausal syndrome; Metabolic syndrome; Obesity; Postmenopausal osteoporosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-syndrome(Prevention) in USA
  • 12 Mar 2012 No development reported - Preclinical for Breast cancer in USA (unspecified route)
  • 12 Mar 2012 No development reported - Preclinical for Colorectal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top